MARKET

MNLO

MNLO

MENLO THERAPEUTC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.720
+0.110
+6.83%
After Hours: 1.700 -0.02 -1.16% 18:02 08/03 EDT
OPEN
1.640
PREV CLOSE
1.610
HIGH
1.720
LOW
1.580
VOLUME
1.94M
TURNOVER
--
52 WEEK HIGH
7.48
52 WEEK LOW
1.000
MARKET CAP
288.31M
P/E (TTM)
-0.5325
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MNLO stock price target is 8.61 with a high estimate of 24.00 and a low estimate of 3.000.

EPS

MNLO News

More
Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6
BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, to
GlobeNewswire · 6d ago
Hedge Funds Have Never Been This Bullish On Menlo Therapeutics Inc. (MNLO)
Insider Monkey · 06/23 18:21
Menlo Therapeutics Inc.'s (NASDAQ:MNLO) Profit Outlook
Simply Wall St. · 06/11 12:34
Menlo Therapeutics: Strong Amzeeq Launch, Recent Zilxi Approval And Positive FCD105 Results Point To Growth Ahead
Seeking Alpha - Article · 06/08 20:10
Why Menlo Therapeutics Stock Sank Today
Motley Fool · 06/05 20:41
Menlo Therapeutics drops 17% after pricing equity offering
Menlo Therapeutics (NASDAQ:MNLO) has priced its public offering of ~27.1M common shares at $1.85/share, for expected gross proceeds of $50,042,500. Underwr
seekingalpha · 06/05 16:13
WORK, PD among premarket losers
Seeking Alpha - Article · 06/05 13:21
Menlo Therapeutics Announces Proposed Offering of Common Stock
GlobeNewswire · 06/04 21:01

Industry

Biotechnology & Medical Research
+3.92%
Pharmaceuticals & Medical Research
+2.05%

Hot Stocks

Symbol
Price
%Change

About MNLO

Menlo Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is focused on developing and commercializing a variety of solutions using its Molecule Stabilizing Technology (MST). The Company has a commercial-stage product, AMZEEQ, and several late-stage product candidates. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough. The Company’s serlopitant is a small molecule, highly selective NK1-R antagonist. It is developing serlopitant as an once-daily oral tablet therapy.
More

Webull offers kinds of Menlo Therapeutics Inc stock information, including NASDAQ:MNLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNLO stock methods without spending real money on the virtual paper trading platform.